Insider Selling: Takeda Pharmaceutical (NYSE:TAK) Insider Sells $2,148,371.59 in Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Andrew Plump sold 116,191 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $18.49, for a total value of $2,148,371.59. Following the sale, the insider owned 145,465 shares in the company, valued at approximately $2,689,647.85. This represents a 44.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Andrew Stewart Plump also recently made the following trade(s):

• On Wednesday, August 19th, Andrew Plump sold 19,651 shares of Takeda Pharmaceutical stock. The stock was sold at an average price of $18.49, for a total transaction of $363,346.99.
• On Monday, August 10th, Andrew Plump sold 165,393 shares of Takeda Pharmaceutical stock. The stock was sold at an average price of $17.10, for a total transaction of $2,828,220.30.

Takeda Pharmaceutical Stock Up 1.5%

NYSE TAK opened at $18.71 on Friday. Takeda Pharmaceutical Co. has a 1-year low of $12.99 and a 1-year high of $18.90. The company has a market capitalization of $59.95 billion, a price-to-earnings ratio of 55.03 and a beta of -0.07. The stock’s 50 day moving average is $17.26 and its two-hundred day moving average is $17.20. The company has a current ratio of 1.14, a quick ratio of 0.62 and a debt-to-equity ratio of 0.58.

Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Thursday, July 30th. The company reported $0.95 EPS for the quarter, topping the consensus estimate of $0.41 by $0.54. The business had revenue of $7.50 billion during the quarter, compared to the consensus estimate of $7.13 billion. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%.Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. Equities analysts forecast that Takeda Pharmaceutical Co. will post 1.54 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on TAK shares. Wall Street Zen upgraded shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Weiss Ratings cut Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, July 30th. Finally, Zacks Research upgraded Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy”.

Institutional Trading of Takeda Pharmaceutical

A number of large investors have recently bought and sold shares of TAK. Capital Research Global Investors lifted its stake in Takeda Pharmaceutical by 0.6% in the fourth quarter. Capital Research Global Investors now owns 13,486,772 shares of the company’s stock valued at $210,259,000 after buying an additional 82,643 shares in the last quarter. UBS Group AG lifted its position in Takeda Pharmaceutical by 46.4% in the 3rd quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock valued at $86,288,000 after acquiring an additional 1,869,323 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in Takeda Pharmaceutical by 100.9% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company’s stock worth $88,596,000 after purchasing an additional 2,854,069 shares during the period. Goldman Sachs Group Inc. increased its holdings in Takeda Pharmaceutical by 15.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock worth $79,120,000 after purchasing an additional 692,404 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Takeda Pharmaceutical by 14.2% in the 1st quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company’s stock valued at $55,358,000 after purchasing an additional 370,800 shares during the period. 9.17% of the stock is owned by institutional investors.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.